Renal Cell Carcinoma (RCC) Clinical Trial Monitor

Active Phase 3 RCC Programs (2026)

Active Phase 2 Programs

The RCC Treatment Landscape in 2026: The Post-IO+TKI Problem

Metastatic clear cell RCC (ccRCC) has undergone two treatment revolutions in 15 years. The first era (2006–2015) established VEGFR-targeted TKIs (sunitinib, pazopanib, axitinib) as standard of care. The second era (2018–present) established IO+TKI combinations — pembrolizumab + axitinib, nivolumab + cabozantinib, pembrolizumab + lenvatinib — as first-line standards, each demonstrating PFS and/or OS benefits over sunitinib.

The resulting unmet need defines the entire 2026 clinical trial agenda: after IO+TKI failure, there is no established second-line standard. Cabozantinib monotherapy, everolimus, and belzutifan are options, but none were studied specifically in the post-IO+TKI setting in their pivotal trials. The field is now running its first wave of purpose-built post-IO+TKI trials.

The Three Key Mechanistic Questions in 2026

• Can HIF-2alpha inhibition + TKI work in adjuvant-recurrent ccRCC? Merck's MK-6482-033 trial (belzutifan + zanzalintinib) directly tests whether the combination addresses the molecular drivers of recurrence after adjuvant therapy — an underexplored population.
• Can a better-tolerated TKI beat everolimus in later-line mRCC? Exelixis's STELLAR-303 tests whether zanzalintinib improves on cabozantinib's efficacy profile with cleaner safety — aiming to become the preferred post-IO option.
• Does neoadjuvant HIF-inhibitor + IO improve surgical outcomes in localized RCC? Dana-Farber's Pre-NEOSHIFT trial addresses cytoreduction before surgery — important for locally advanced disease where resectability is borderline.

Merck's LITESPARK Program: Mapping the Belzutifan Expansion

Belzutifan (Welireg) received initial FDA approval in 2021 for VHL-associated ccRCC/hemangioblastomas/pNETs — rare, germline-mutation-driven tumors. The LITESPARK program then expanded into sporadic (non-VHL germline) ccRCC:

• LITESPARK-011 — belzutifan vs everolimus in previously-treated ccRCC: positive OS data (2024), reinforcing belzutifan's role in relapsed/refractory ccRCC and driving second FDA approval.
• LITESPARK-005 — pembrolizumab + belzutifan vs pembrolizumab + lenvatinib in first-line ccRCC: results awaited; tests whether HIF-2alpha inhibition can replace TKI as the IO partner.
• MK-6482-033 (NCT07227402) — belzutifan + zanzalintinib in adjuvant-recurrent ccRCC: targets the specific population that recurred despite or after adjuvant therapy (sunitinib, pembrolizumab), where the HIF-pathway is likely still dominant and dual targeting of HIF-2alpha + VEGFR may provide additive benefit.

FAQ: Renal Cell Carcinoma Clinical Trials

What is belzutifan (Welireg) and why is it uniquely suited to ccRCC?

Belzutifan is the first approved HIF-2alpha inhibitor. It binds directly to the PAS-B domain of HIF-2alpha, blocking its heterodimerization with ARNT — preventing formation of the active transcription factor complex. Because HIF-2alpha accumulation (due to VHL loss) is the initiating oncogenic event in ~90% of clear cell RCC, belzutifan targets the molecular driver of the disease rather than a downstream consequence. This distinguishes it mechanistically from all approved TKIs (which target the VEGF/VEGFR axis that HIF-2alpha activates) and IO agents (which reverse immune suppression downstream of HIF activity). Response rates of ~25–40% in VEGFR-pretreated ccRCC patients make belzutifan a meaningful option in a tumor where options after two prior lines have historically been limited to everolimus (low response rate) or cabozantinib.

Who qualifies for active RCC clinical trials in 2026?

Eligibility varies by trial, but most RCC Phase 2/3 programs require: histologically confirmed clear cell RCC (non-clear cell histologies are usually excluded or in separate cohorts); measurable disease per RECIST 1.1; ECOG performance status 0–1; adequate renal, hepatic, and hematologic function; and a defined prior therapy profile. The MK-6482-033 trial specifically enrolls patients who recurred after adjuvant therapy (prior sunitinib or pembrolizumab-based adjuvant treatment). The STELLAR-303 trial enrolls patients who received at least one prior systemic therapy including a checkpoint inhibitor. Trials testing IO combinations generally exclude patients who progressed on prior PD-1/PD-L1 therapy within a specified window.

What is the difference between clear cell RCC and non-clear cell RCC for trial eligibility?

Clear cell RCC (ccRCC) represents approximately 70–75% of all kidney cancers and is defined by loss of the VHL gene and characteristic clear cytoplasm on histology. It is the predominant histology in virtually all Phase 3 RCC trials. Non-clear cell RCC (nccRCC) encompasses papillary RCC (type 1 and 2), chromophobe RCC, collecting duct carcinoma, translocation RCC, and medullary carcinoma — each with different biology and treatment sensitivities. Most nccRCC does not respond to VEGFR-targeted therapy as robustly as ccRCC, and IO outcomes are variable. Several dedicated nccRCC trials exist (NCI's PAPMET2, etc.), but the trials on this page are predominantly clear cell unless otherwise noted. Always verify histology requirements in individual eligibility criteria.

How is DataLookout different from a manual ClinicalTrials.gov search for "renal cell carcinoma"?

A manual ClinicalTrials.gov search for "renal cell carcinoma" returns hundreds of trials — including Phase 1 dose-escalation studies, observational registries, genetic studies, biomarker collections, and quality-of-life assessments — alongside the Phase 3 programs that actually matter for treatment decision-making. DataLookout monitors keyword profiles for protocol amendments, new trial postings, and enrollment status changes, delivering a focused daily digest of the trials you've flagged. Set one profile for "Phase 3 ccRCC recruiting" and a second for "belzutifan" to track Merck's LITESPARK program — without duplicates or noise from tangentially related studies.

Related Pages

• Kidney Cancer Clinical Trials (all histologies)
• Bladder Cancer / Urothelial Carcinoma Trials
• Prostate Cancer Clinical Trials
• Non-Hodgkin Lymphoma Clinical Trials